NVAX Stock Forecast: Novavax rises as Gilead's remdesivir receives FDA stamp for covid


  • NASDAQ: NVAX is set to extend its gains on Friday after closing higher on Thursday. 
  • Novavax focuses on developing a vaccine for COVID-19 and is benefiting from Gilead's success.
  • Surging European coronavirus cases are also raising the stakes for NVAX's shares.

Everybody – including President Donald Trump – wishes covid would just disappear and let everybody live their lives. Yet the opposite is happening. Novavax (NASDAQ: NVAX) is developing a vaccine for the disease that is gripping the world and may benefit from authorities' willingness to approve solutions.

The US Food and Drugs Administration (FDA) has approved a Gilead's treatment called remdesivir used by Trump among many others. Stocks of the pharmaceutical firm surged, carrying higher other firms involved in immunization or a cure to covid

The Gaithersburg, the Maryland-based company, has received funds from the White House's Operation Warp Speed (OWS) program toward a vaccine. While several competitors are already engaged in Phase 3 trials, these will not necessarily be successful. Moreover, more than one solution may be needed.

Interest in coronavirus cures is also growing due to a severe winter wave raging in Europe. Infections are leaping across the old continent and have already resulted in lockdowns and curfews. Covid cases are also on the rise in the US, potentially culminating in a third peak. Colder states such as Wisconsin and Minnesota see the worst surges, but hospitalizations are also on the rise in southern states. 

NVAX Stock Forecast

Novavax Inc's shares have closed at $93.59 on Thursday, up some 2.67%. Friday's pre-market trading is showing potential for additional gains, of around 1%. The round $100 mark is the next level to watch.

That is still only half of the firm's 52-week peak of $189.40, but an improvement after several down days. NVAX's shares have come a long way from the 52-week low of $3.54.

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.

Feed news

Latest Forex News


Latest Forex News

Editors’ Picks

EUR/USD losses 1.1900 amid dollar’s comeback

EUR/USD has extended its gains, nearing 1.1950, but quickly turned negative now trading around 1.1880. The greenback recovers as equities fall as the market’s sentiment turns sour.

EUR/USD News

GBP/USD retreats from daily highs, holds around 1.3350

GBP/USD retreats from near 1.3400, partially undermined by Brexit woes but mostly on renewed dollar’s demand. Doubts arise about Chief EU Negotiator Barnier traveling to London.

GBP/USD News

XAU/USD trades with modest gains above $1810 level, lacks follow-through

A softer tone surrounding the USD assisted gold to gain some traction on Thursday. COVID-19 vaccine optimism might cap the upside for the safe-haven precious metal. Holiday-thinned liquidity warrants some caution before placing fresh directional bets.

Gold news

US Thanksgiving Wrap: Consumers carry October, November starts to look dicey

A triple dose of US data on Wednesday before the Thanksgiving holiday confirmed the strength of the consumer recovery even as employment problems again loom from the rising numbers of Covid-19 closures across the country.

Read more

Black Friday 2020 Discounts!

Learn to trade with the best! Don't miss the most experienced traders and speakers in FXStreet Premium webinars. Also if you are a Premium member you can get real-time FXS Signals and receive daily market analysis with the best forex insights!

More info

Forex MAJORS

Cryptocurrencies

Signatures